[eDisclosure Notice] KOSDAQ - 27th

◆KainosMed=Signed a technology transfer agreement for the neurological disease treatment KM819 with the U.S. company FAScinate Therapeutics, Inc.

◆Hanamicron=Clarified that it is reviewing mid- to long-term business cooperation regarding reports on the D-RAM post-process consignment contract with SK Hynix.

◆Amicogen=Decided on a new facility investment worth 61 billion KRW to produce raw materials for biopharmaceuticals and develop biopharmaceutical CDMO.

◆Caregen=KOSDAQ Market Headquarters announced a preliminary designation as an unfaithful disclosure company due to reversal of disclosure related to termination of a single sales and supply contract.